[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Condition

Nonalcoholic Steatohepatitis (NASH)

Treatment type

Interventional

Investigational product

BMS-986263

Phase

Phase 2

Sponsor

Bristol-Myers Squibb

ClinicalTrials.gov identifier

NCT04267393

Study number

IM025017

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

Randomized study to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH)

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria
  1. Participants with liver biopsy fibrosis score stage 4 performed within 6 months
  2. Men and women must agree to follow methods of contraception
Exclusion criteria
  1. Worsening liver disease or any disease might compromise participant safety in the opinion of the investigator
  2. Known immunocompromised status or any disease or condition which might compromise participant safety
  3. Prior exposure to BMS-986263
  4. Clinically relevant abnormal physical examination, vital signs, ECG, or clinical laboratory tests
  5. Hepatic decompensation Other protocol-defined inclusion/exclusion criteria apply

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site